Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

Wall of faces

In January 2020, ISARIC launched the dedicated COVID-19 Clinical Characterisation Protocol (CCP) and Case Report Forms (CRF) as well as a free data management platform for researchers to upload their clinical data, globally. The database was open and publicly accessible from 23 January, 2020, when less than a thousand COVID-19 cases had been reported globally.

‘I remember I kept refreshing the database page, waiting for the first patient records to come through,’ said James Lee, ISARIC Senior Clinical Trials Manager.

On 13 February, the first patient record was successfully uploaded onto the platform. Barely a month later, this number reached 10K records.  Now, 18 months into the pandemic, there are more than half-a-million records, and the ISARIC clinical data platform has grown to become the largest international individual patient dataset of COVID-19 hospitalised cases.

Read the full story on the University of Oxford website.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.